Michael Steinmetz

Homestead Clinical Corp. develops pharmaceutical products. It develops diagnostic, prognostic, and theranostic tools which is used for the diseases such as cancer, diabetes, and AIDS. The company was founded by Leroy E. Hood in June 2005 and is headquartered in Seattle, WA.

Allozyne, Inc. operates as a biotechnology company that develops and manufactures pharmaceutical products. The firm focuses on manufacture of protein therapeutics for the medical need in autoimmune diseases and cancer. The company was founded by David A. Tirrell, Deepshikha Datta, and William A. Goddard, III in March 2004 and is headquartered in Seattle, WA.

Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI.

Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA.

Virdante Pharmaceuticals, Inc. develops and commercializes drugs for auto-immune and inflammatory disorders. The company's products incorporate a proprietary 'sialic switch' technology to improve the anti-inflammatory properties of antibodies. It was founded in 2008 and is headquartered in Cambridge, MA.

Oxford Immunotec Global Ltd. operates as a diagnostics company, which develops and commercializes proprietary tests for immunology and infectious disease. Its products include T-SPOT.TB, T-SPOT.CMV, T-SPOT.PRT and T-CELL XTEND. The company was founded by Peter James Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA.

Oxford Immunotec Ltd. operates as a medical diagnostic company. It develops and sells medical diagnostic products. The company was founded by Peter Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom.

Intracel Resources LLC specializes in the development of cardiovascular disease research solutions. Its products include spectrum encompasses lipoproteins, human lipoprotein-deficient serums and cell growth supplements. The company also supply immunotherapeutic vaccines and drugs for liposuction uses and cardiovascular applications. The company was founded in 1985 and is headquartered in Frederick, MD.

TaiGen Biotechnology Co., Ltd. is a research-based and product-driven pharmaceutical company engaging in the development of therapeutics for infectious diseases, cancer, and diabetes-related complications. Its activities include drug discovery, development, global regulatory, and commercialization in China. The company was founded by Ming-Chu Hsu in 2001 and is headquartered in Taipei, Taiwan.

Part of SpecialtyCare, Inc., PhysIOM LLC provides intraoperative neurophysiologic monitoring services. The company is based in Fort Collins, CO. PhysIOM was acquired by ProNerve LLC on December 20, 2012.

Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts.

Viral Logic Systems Technology Corp. provides pharmaceutical products and services. It develops treatments for autoimmune, inflammatory diseases and disorders. The company was founded by Steven R. Wiley and Craig A. Smith in 2004 and headquartered in Seattle, WA.

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Clarus Lifesciences II LP seeks investment opportunities in companies located in the US. The fund targets companies operating in the fields of specialty pharmaceuticals, biotechnology and medical devices. It provides financing for early stage capital requirements with an investment size of USD 20 - 60 million.

Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland.

Quest Diagnostics TB LLC develops and sells clinical diagnostic products. It focused on developing proprietary tests for the management of immune-regulated conditions. The company was founded by Dr. Peter Wrighton-Smith in 2002 and is headquartered in Malborough, MA.

VBI Vaccines, Inc. is a biopharmaceutical company. It engages in the development of eVLP vaccine platform for the design of (e) virus-like-particle vaccines that closely mimic the target virus. The company also involves in the development of thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI Vaccines was founded on July 25, 2014 and is headquartered in Cambridge, MA.